"Ig, I'm sure he's working to raise money through partnering deals, but that's not "news" of any meaningful kind IMHO -- that's what biotech CEO's are ALWAYS doing -- it's their core job."
But that is my point, Meisha. The company has clearly decided to change course, going from a "preserve rights and dilute" plan to a "sell or license rights" approach. This is most likely the reason DOC was ousted, due to his preference for the latter option, which became untenable due to the share price suppression. So when you say that everyone assumes CEOs are always looking to make deals so why bother mentioning it(?), in this case it actively confirms that ADXS is changing course and that they are working on accretive deals. And I am fairly certain that this issue--in what manner will they raise capital--is of primary concern to both the legitimate "market" and the short manipulators.